Get started
Author

Eugenia Ortega

Mutations in BRIP1 confer high risk of ovarian cancer
2011 · Thorunn Rafnar, Daniel F Gudbjartsson, et al. · Nature Genetics · 412
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer
2014 · Lorena Alonso-Alconada, Laura Muinelo-Romay, et al. · Molecular Cancer · 107
PDF
Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus
2010 · Simon N. Stacey, Patrick Sulem, et al. · PLoS Genetics · 104
PDF
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
2019 · Ignace Vergote, Giovanni Scambia, et al. · The Lancet Oncology · 91
PDF
Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)
2023 · Jose Alejandro Pérez-Fidalgo, Eugenia Ortega, et al. · Therapeutic Advances in Medical Oncology · 61
Endometrial Carcinoma: Specific Targeted Pathways
2016 · Nuria Eritja, Andree Yeramian, et al. · Advances in experimental medicine and biology · 59
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2023 · Raphaël Leman, Etienne Muller, et al. · Clinical Cancer Research · 34
PDF
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
2023 · N. Colombo, A. Gadducci, et al. · British Journal of Cancer · 28
PDF
Gemcitabine/Capecitabine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
2005 · Beth Andres, Jose Ignacio Mayordomo, et al. · Clinical Breast Cancer · 25
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck
2023 · Jordi Rubió-Casadevall, Beatriz Cirauqui Cirauqui, et al. · Frontiers in Oncology · 16
Immunocryosurgery as monotherapy for lentigo maligna or combined with surgical excision for lentigo maligna melanoma
2018 · Clara Matas‐Nadal, Xavier Sòria, et al. · The Journal of Dermatology · 15
Prognostic Significance and Diagnostic Value of Protein S-100 and Tyrosinase in Patients With Malignant Melanoma
2008 · Raquel Andrés, Jose I. Mayordomo, et al. · American Journal of Clinical Oncology · 15
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
2019 · Ignacio Romero, Pedro Mallol, et al. · Anti-Cancer Drugs · 10
Targeted therapies in gynecologic cancers and melanoma
2008 · Eugenia Ortega, Rosa M. Marti, et al. · Seminars in Diagnostic Pathology · 7
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer
2016 · Antonio González-Martin, Patricia Pautier, et al. · International Journal of Gynecological Cancer · 6
Prognostic factors in undifferentiated uterine sarcoma: a subanalysis of the SARCUT study
2023 · Ronalds Macuks, Yusuf Yildirim, et al. · Archives of Gynecology and Obstetrics · 4
PDF
Impact of Hospital Case Volume on Uterine Sarcoma Prognosis: SARCUT Study Subanalysis
2023 · Mikel Gorostidi, Yusuf Yildirim, et al. · Annals of Surgical Oncology · 3
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)
2026 · Florence Joly, Amélie Anota, et al. · JNCI Journal of the National Cancer Institute · 1
PDF
Targeting the Proteasome in Melanoma
2011 · Anabel Sorolla, Andree Yeramian, et al. · InTech eBooks · 1
PDF
Adjuvant Radiotherapy in the Oldest-Old: A National Spanish Multicenter Analysis of Endometrial Cancer Patients Aged ≥ 80 Years
2026 · Ángeles Rovirosa, Pedro Muñoz, et al. · Journal of Personalized Medicine
Supplementary Table S4 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S3 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Appendix S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Table S6 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
Supplementary Figure S1 from Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer
2025 · Raphaël Leman, Etienne Muller, et al.
PDF
Works count: 53
Citation count: 999
H-index: 12
I10-index: 13
Year
Topic
Type